Department of Clinical Oncology, Building 1, K1-P, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Trends Immunol. 2011 Mar;32(3):97-103. doi: 10.1016/j.it.2010.12.006. Epub 2011 Jan 10.
Persistent viral infections reflect a failure of the host's immune system to control infection, and in many cases, they are associated with the development of malignancies. So far, vaccines designed to boost viral immunity during chronic infection have not been successful. Infections with high-risk human papilloma viruses (e.g. HPV16) are acquired by a large segment of the population and persist in 5-10% of infected individuals, which causes the development of high-grade pre-malignant lesions. Recently we succeeded in causing regression of HPV16-induced disease in ∼50% of chronically infected patients by a novel therapeutic vaccine. Here, we summarize the parallels in immunity against HPV and other chronic viruses and discuss the general implications of our findings for the immunotherapy of chronic infections.
持续性病毒感染反映了宿主免疫系统未能控制感染，在许多情况下，它们与恶性肿瘤的发展有关。到目前为止，旨在增强慢性感染期间病毒免疫的疫苗并未成功。高危型人乳头瘤病毒（例如 HPV16）的感染被很大一部分人群获得，并在 5-10%的感染者中持续存在，导致高级别癌前病变的发展。最近，我们通过一种新型治疗性疫苗成功地使大约 50%的慢性感染患者的 HPV16 诱导的疾病消退。在这里，我们总结了针对 HPV 和其他慢性病毒的免疫的相似之处，并讨论了我们的发现对慢性感染免疫治疗的一般意义。
